PRINCETON, N.J., April 30, 2024 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (NASDAQ:IART), a leading global medical technology company, is pleased to announce that following a successful Q1 2024 U.S. relaunch of its CereLink® ICP Monitoring System, the innovative product will be featured at the upcoming AANS Annual Scientific Meeting from May 3 through 6, 2024, in Chicago, Illinois. The CereLink ICP Monitoring System provides clinicians with uncompromised advanced continuous ICP monitoring ...

PRINCETON, N.J., April 18, 2024 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (NASDAQ: IART), a leading global medical technology company, today announced that it has rescheduled the release of the Company’s first quarter 2024 financial results to Monday, May 6, 2024. In conjunction with the earnings release, Integra’s management team will host a conference call at 8:30 a.m. EDT. A live webcast will be available on the Investors section of the Company’s website at investor.integralife.com. F ...

PRINCETON, N.J., April 18, 2024 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (NASDAQ: IART), a leading global medical technology company, today announced that it has rescheduled the release of the Company’s first quarter 2024 financial results to Monday, May 6, 2024. In conjunction with the earnings release, Integra’s management team will host a conference call at 8:30 a.m. EDT. A live webcast will be available on the Investors section of the Company’s website at investor.integralife.com. F ...

Integra LifeSciences Holdings Corporation (IART) is well-poised to grow in the coming quarters, given the healthy demand for its industry-leading products within Codman Specialty Surgical (“CSS”). The company’s strong overseas performance is encouraging, while strategic initiatives undertaken will help reach a wider customer base. In addition, efforts to optimize the portfolio with new acquisitions and product developments buoy optimism. Meanwhile, headwinds from currency fluctuations and escalated expenses ...

Revenue and Segment Performance - Codman Specialty Surgical (CSS) segment represents approximately two-thirds of the company's total revenue, while Tissue Technologies (TT) segment accounts for about one-third[19] - The company's CSS segment is a global leader in neurosurgery and one of the top three providers in precision, specialty, and general surgical instruments[19] - The company's TT segment focuses on complex wound surgery, surgical reconstruction, and peripheral nerve repair, with products like Integra Dermal Matrices and NeuraGen®[33] - The CSS business has experienced growth driven by geographic expansion and new product registrations in markets such as China, Japan, and Europe, with expectations for continued growth in the near-to-long term[44] - Q4 revenues tend to be stronger due to increased hospital purchases aligning with budget cycles, with Q1 typically having lower revenues[55] Product Development and Launches - The company completed enrollment in the DuraSorb U.S. IDE clinical study for two-stage breast reconstruction in June 2023, with FDA approvals expected in 2025[23][42] - In 2023, the company launched CUSA® Clarity Tips for surgical procedures and expanded its product offerings in international markets, including MicroMatrix® and Certas Plus® Programmable Valve in Europe[23][24] - The company received FDA 510(k) clearance for MicroMatrix® Flex in 2023[43] - The CUSA Clarity platform was updated with new ultrasonic handpiece and integrated electrosurgical capabilities, and a modified 23 kHz CUSA Electrosurgery Module (CEM) for Clarity handpieces was launched in August 2023[44] - The Aurora Surgiscope, a single-use medical device for cranial surgery, received 510(k) clearance from the FDA in Q4 2023[46] - The CereLink® ICP Monitor System was voluntarily removed globally in 2022 due to out-of-range readings, but the company received 510(k) clearance from the FDA on February 4, 2024, with plans to resume U.S. shipments in Q1 2024[48] Acquisitions and Strategic Expansions - The company acquired Acclarent, Inc. in December 2023 to strengthen its ENT product portfolio and expand its presence in the ENT segment[23] - The company has acquired two businesses between January 2021 and December 2023 for a total cost of $358.4 million, including ACell, Inc. for $306.9 million and Surgical Innovation Associates, Inc. for $51.5 million[111] - The company entered into a definitive agreement to acquire Acclarent from Johnson & Johnson for $275.0 million in cash, with an additional $5.0 million payment upon achieving a regulatory milestone[113] - The company's new facility in Suzhou, China, is part of its In-China-For-China strategy to expand assembly capabilities[24] Regulatory Compliance and Quality Assurance - The company initiated a voluntary global recall of products manufactured at the Boston facility in Q2 2023, including Primatrix®, Surgimend®, Revize™, and TissueMend™[41] - The company is subject to extensive FDA regulations, including Quality System Regulation and Good Manufacturing Practices, which can impact product approvals and manufacturing[58] - The company's manufacturing facilities are subject to FDA inspections and must comply with Quality System Regulations, with most participating in the Medical Device Single Audit Program[70] - The company received a warning letter from the FDA related to quality system issues at its Boston manufacturing facility, impacting commercial distribution of products manufactured there[150] - The company initiated a voluntary global recall of all products manufactured at its Boston facility between March 1, 2018, and May 22, 2023[154] International Operations and Market Expansion - The company's international operations are subject to various laws and regulations, including the U.S. Foreign Corrupt Practices Act and local anti-bribery laws, which could restrict or prevent sales in certain countries[118] - The company's global business is exposed to operational and economic risks, including potential disruptions from trade tensions, tariffs, and geopolitical events such as the Russia-Ukraine conflict[120][121] - The company generates significant revenues in multiple foreign currencies, exposing it to currency exchange risk, particularly with transactions in Australian dollars, British pounds, Canadian dollars, Chinese yuan, Euros, Japanese yen, and Swiss francs[123] - The company's growth strategy involves expanding existing foreign operations and entering new jurisdictions, which may be complicated by customer acceptance, regulatory restrictions, and unfamiliar distribution channels[119] Financial Performance and Shareholder Returns - The company's total consolidated external debt as of December 31, 2023, was approximately $1.4 billion[171] - The company repurchased 928,485 shares at an average price of $37.17 per share during October 2023, as part of a $225 million stock repurchase program[207] - The company entered into a $125 million accelerated share repurchase (ASR) in August 2023, receiving 2.3 million shares initially and an additional 0.9 million shares upon early exercise[207] - The company accrued $2.5 million in excise tax related to share repurchases under the Inflation Reduction Act of 2022[209] - The company's Board authorized a new $225 million share repurchase program in July 2023, expiring on December 31, 2025, with $100 million remaining authorized as of December 31, 2023[210] - The company's cumulative shareholder return over five years (2018-2023) is compared to the S&P 500 and S&P Healthcare Equipment Index, based on a $100 investment[213] Competitive Landscape and Market Risks - The medical device industry is highly competitive, with competitors potentially offering lower-cost products or better reimbursement options[107] - The company's ability to compete effectively may be hindered by competitors with greater financial, technical, and marketing resources[107] - The company's profitability could be adversely affected by competitive pressures, including price competition, technological advancements by competitors, and changes in reimbursement rates[108][109] - The company's future success depends on its ability to compete effectively, respond to technological advances, and meet changing customer and regulatory requirements[108] - Market acceptance of the company's products depends on factors such as convincing customers of the technology's superiority, manufacturing efficiency, and favorable reimbursement status[130] Supply Chain and Operational Risks - The company maintains long-term supply contracts and sufficient inventory to mitigate disruptions in raw material availability, though some components are sourced from limited suppliers[50] - The company faces risks from global supply constraints, which could increase manufacturing costs and impact the availability of raw materials and components[140] - The company's supply chain and cost of goods may be negatively impacted by unanticipated price increases due to global economic disruptions, inflation, and geopolitical events[136] - The company may experience difficulties, delays, or unexpected costs from consolidating facilities and transferring manufacturing operations[138] - The company's facilities and suppliers are at risk of damage or disruption from natural disasters, geopolitical events, or other unforeseen circumstances[139] - The COVID-19 pandemic has caused disruptions in the global supply chain, including material shortages and increased costs for raw materials and logistics[174] Regulatory and Legal Risks - The company is subject to stringent domestic and foreign medical device regulations, and any adverse action could impact its ability to compete and its financial condition[144] - Compliance with the European Medical Device Regulation (MDR) has cost the company $46.6 million in 2023, with additional expenditures anticipated for ongoing certification efforts[147] - The company is subject to the U.S. Foreign Corrupt Practices Act (FCPA) and other international anti-bribery laws, with potential risks in its interactions with healthcare professionals abroad[152] - The company's products are subject to FDA and international regulatory reporting requirements, including recalls, which could harm its reputation and financial results[154][155] - The company faces risks from healthcare reform initiatives, including potential changes in FDA clearance processes and increased pricing pressures[156][158] - The company is subject to environmental, health, safety, and transportation laws, which may increase compliance costs and expose it to potential liabilities[163][164] - The company faces risks related to climate change, including physical risks to facilities and supply chain disruptions, as well as potential regulatory changes[165] - The company's business may be adversely affected by evolving environmental, social, and governance (ESG) expectations and regulations, potentially impacting investor and customer decisions[166] Intellectual Property and Cybersecurity - The company's intellectual property rights may not provide significant competitive advantage, and patents could be challenged or invalidated[177] - The company relies on unpatented trade secrets, which are difficult to protect and could be independently developed by competitors[178] - Cybersecurity risks are heightened due to reliance on internet technology and remote work, increasing vulnerability to cyber-attacks[184] - The company faces potential financial penalties and reputational harm if it fails to comply with data privacy laws such as HIPAA and GDPR[186] - The company maintains a comprehensive cybersecurity program, including regular audits and penetration tests, to protect sensitive information[188] - The company has not experienced any material cybersecurity incidents as of December 31, 2023, but acknowledges ongoing risks from cyber-attacks, ransomware, and other threats[195] Employee and Workforce Management - As of December 31, 2023, the company had approximately 3,946 regular full and part-time employees and 1,383 contingent, subcontracted, and outsourced partners, with 70% located in the United States[89] - The company expanded its Employee Resource Groups (ERGs) to seven in fiscal year 2023, focusing on diversity, inclusion, and career development[90] - The company conducts regular pay equity analyses to ensure fair compensation practices, adjusting pay as necessary based on role and scope[92] - The company offers comprehensive health and wellbeing programs, including health insurance, disability coverage, parental leave, and on-demand health advocates[98] - The company faces significant competition for key personnel, particularly in regions with labor shortages and remote work trends[167] Financial and Tax Risks - The company may incur additional tax liabilities due to changes in tax laws, including the adoption of a 15% global minimum tax regime in several jurisdictions[169] - The company's debt service obligations could impede growth by diverting cash flow from business expansion and acquisitions[172] - The company may face impairments or other charges related to goodwill and indefinite-lived intangible assets, which could materially affect its financial results[125] - The company may need to record impairment charges or accelerate amortization on certain trade names or technology-related intangible assets due to discontinued products or profitability assessments[128] Product Liability and Market Acceptance - The company is exposed to product liability claims, and its insurance may not cover all potential claims or be renewed at comparable costs[141] - Economic and political instability could reduce orders for the company's products or interrupt production and distribution[142] - Market acceptance of medical products depends on reimbursement policies, with potential impacts from legislative or regulatory reforms to reimbursement systems[76][77] - The company's products derived from animal sources, particularly bovine tissue, are subject to scrutiny and potential regulatory bans in certain countries due to concerns over disease transmission[160][161][162] - 43.4% of the company's 2023 revenue came from products containing materials derived from bovine tissue[160] Facilities and Operations - The company leases approximately 166,991 square feet of space in Princeton, NJ, for its principal headquarters, with the lease expiring in 2035[196] - The company operates manufacturing and research facilities in multiple locations globally, including the U.S., Europe, and Asia, with FDA-registered facilities[197] - The company's common stock trades on the Nasdaq Global Select Market under the symbol "IART," with approximately 749 stockholders of record as of February 27, 2024[202] Research and Development - The company's regenerative technology platform includes FDA-approved products for dermal tissue regeneration and peripheral nerve repair[40][43] - The CerebroFlo® EVD catheter with Endexo® technology demonstrated an average of 99% less thrombus accumulation compared to a market-leading EVD catheter in vitro[45] - The company focuses on surgical, neurologic, and regenerative care, with product lines developed from its engineered collagen technology platform[217] Data Privacy and Security - The company is subject to strict data privacy and security regulations, including the EU General Data Protection Regulation (GDPR), which imposes significant fines for non-compliance and requires prompt notice of data breaches[84] - Compliance with data privacy laws may require changes in business practices, complicate operations, and impact clinical research activities and product offerings involving clinical data[86]

Integra LifeSciences Holdings Corporation. (NASDAQ:IART) Q4 2023 Earnings Conference Call February 28, 2024 8:30 AM ET Company Participants Christopher Ward - Senior Director of Investor Relations Jan De Witte - President and Chief Executive Officer Lea Knight - Chief Financial Officer Conference Call Participants Vik Chopra - Wells Fargo Kristen Stewart - CL King Ryan Zimmerman - BTIG Jayson Bedford - Raymond James Robert Marcus - JPMorgan Steven Lichtman - Oppenheimer Richard Newitter - Truist Securities ...

Note: Organic growth; Adj EBITDA and Adj EPS are non-GAAP financial measure. 6 IART Q4 2023 Earnings Presentation Note: Adj. EBITDA margin, and adj. EPS are non-GAAP financial measures. Codman Specialty Surgical Q4 Revenue Adj. EBITDA Margin 25.3% (230bps) vs. 2022 Q4 Revenue and adj. EPS within guidance range Tissue Technologies Q4 Revenue Revenues Q4'23 Q4 Growth Q4 Growth excl. Boston Organic1 $122.7M (8.0%) 6.9% 7.2% | --- | --- | --- | |----------------------|------------------------------------------- ...

News Release Integra LifeSciences Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides 2024 Financial Guidance Princeton, New Jersey, February 28, 2024 - Integra LifeSciences Holdings Corporation (NASDAQ: IART) today reported financial results for the fourth quarter and full year ended December 31, 2023. Fourth Quarter 2023 Full-Year 2023 Business Highlights "In 2023, we saw stability in our markets and resilience of our product portfolio, which demonstrates the impact of our products an ...

COMMISSION FILE NO. 000-26224 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 INTEGRA LIFESCIENCES HOLDINGS CORPORATION (EXACT NAME OF REGISTRANT AS SPECIFIED IN ITS CHARTER) Delaware 51-0317849 (STATE ...

Integra LifeSciences Holdings Corporation (NASDAQ:IART) Q3 2023 Earnings Call October 25, 2023 8:30 AM ET Company Participants Chris Ward - Senior Director of Investor Relations Jan De Witte - President and Chief Executive Officer Lea Daniels Knight - Chief Financial Officer Conference Call Participants Young Li - Jefferies Vik Chopra - Wells Fargo Robbie Marcus - J.P. Morgan Ryan Zimmerman - BTIG Craig Bijou - Bank of America Securities Richard Newitter - Truist Securities Steven Lichtman - Oppenheimer and ...